REHOVOT, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Foamix, a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams for dermatology for itself and major pharmaceutical licensees, today announced that Dr. Dov Tamarkin, Chief Executive Officer, will speak at the Cowen & Company 34th Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, March 3-5, 2014. Dr. Tamarkin will provide an overview of the Company's business and commercial strategy. He will reveal successful results from Phase 2 Acne and Impetigo (including MRSA impetigo) clinical trials; and how the Company is transforming from a technology-based, licensing company into a commercial specialty pharmaceutical company.
Details of the presentation are as follows:
Date: Monday, March 3, 2014
Time: 3:30 p.m. EST
Location: The Boston Marriott Copley Place, Boston, Massachusetts
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company focused on the development of patented topical foams for dermatology. The Company's lead product, Minocycline Foam, is the first-ever topical minocycline which can be used for the treatment of acne, skin infections and rosacea. Minocycline is a well-known broad-spectrum oral antibiotic, which Foamix has uniquely transformed into a topically-applied, patented-form of the drug, thereby increasing efficacy, speed of action and minimizing side effects. The Company has successfully completed Phase 2 clinical trials in acne and impetigo using its patented foam delivery platform with Minocycline. Besides these clinical stage drugs, Foamix has many pipeline drugs for dermatology and other indications using its unique topical minocycline or doxycycline and its patented delivery technologies in pre-clinical and pilot study stages.
As the IP technology leader in foams, Foamix has licensed various forms of its patented foam to Bayer, Merz, Actavis, Round Table Group and Arkin Dermatology, all of which are in Phase 2 or Phase 3 clinical trials using their own active pharmaceutical ingredients.
To date, Foamix has 25 issued patents in the United States and 58 granted patents worldwide.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will,""plan," "could," "may" and similar expressions are intended to identify forward-looking statements.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions.
The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Michael Rice Founding Partner LifeSci Advisors, LLLC 646-597-6979 email@example.com Dov Tamarkin CEO Foamix Ltd. firstname.lastname@example.org Dorit Hayon Business Development Manager Foamix Ltd. email@example.comSource:Foamix, Ltd.